B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.06 +0.87 (+1.80%)
Streaming Delayed Price Updated: 2:57 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,062,420
Open 49.08
Bid (Size) 49.05 (6)
Ask (Size) 49.06 (15)
Prev. Close 48.19
Today's Range 48.36 - 49.21
52wk Range 46.90 - 139.74
Shares Outstanding N/A
Dividend Yield 4.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga

Performance

YTD
-43.9%
-43.9%
1 Month
-29.2%
-29.2%
3 Month
-29.0%
-29.0%
6 Month
-40.6%
-40.6%
1 Year
-61.1%
-61.1%

More News

Read More
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Via Benzinga
Why Is Novo Nordisk Stock Crashing, and Is It a Buying Opportunity?
Via The Motley Fool
Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure
Via Benzinga
Topics Economy Government
Why Eli Lilly Stock Topped the Market Today
Via The Motley Fool
Topics Government
Why Novo Nordisk Stock Bumped Higher on Friday
Via The Motley Fool
Topics Government
Will Hims & Hers Fall Along With Novo Nordisk?
Via MarketBeat
Why Novo Nordisk Stock Imploded This Week
Via The Motley Fool
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare
Via Stocktwits
Topics Government
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
Via Benzinga
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients
Via Benzinga
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
Via Benzinga
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Why Novo Nordisk Stock Crumbled Again Today
Via The Motley Fool
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Via Benzinga
Why Novo Nordisk Stock Plummeted Today
Via The Motley Fool
Topics Stocks
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Novo Nordisk Hit With Stock Downgrades After Lowering Full-Year Outlook: But Retail Is Optimistic On Company’s Profitability
Via Stocktwits

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.06
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 08/04/25 02:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.